Torsemide: Advanced Loop Diuretic for Effective Fluid Management
Torsemide
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.50 | $45.00 (0%) | 🛒 Add to cart |
| 120 | $0.45 | $60.00 $54.00 (10%) | 🛒 Add to cart |
| 180 | $0.39 | $90.00 $70.00 (22%) | 🛒 Add to cart |
| 270 | $0.36 | $135.00 $97.00 (28%) | 🛒 Add to cart |
| 360 | $0.34
Best per pill | $180.00 $121.00 (33%) | 🛒 Add to cart |
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.88 | $53.00 (0%) | 🛒 Add to cart |
| 90 | $0.80 | $79.50 $72.00 (9%) | 🛒 Add to cart |
| 120 | $0.76 | $106.00 $91.00 (14%) | 🛒 Add to cart |
| 180 | $0.72 | $159.00 $129.00 (19%) | 🛒 Add to cart |
| 270 | $0.69 | $238.50 $185.00 (22%) | 🛒 Add to cart |
| 360 | $0.67
Best per pill | $318.00 $242.00 (24%) | 🛒 Add to cart |
Synonyms | |||
Torsemide is a potent loop diuretic indicated for the management of edema associated with congestive heart failure, renal disease, and hepatic cirrhosis. It acts on the ascending limb of the loop of Henle to inhibit sodium and chloride reabsorption, promoting significant aquaresis. Clinicians favor torsemide for its predictable pharmacokinetics, high bioavailability, and longer duration of action compared to other agents in its class, making it a cornerstone therapy in comprehensive decongestive strategies.
Features
- Chemical structure: sulfonylurea class loop diuretic
- Mechanism: selective inhibition of the Na⁺/K⁺/2Cl⁻ cotransporter in the thick ascending limb
- High oral bioavailability (~80-90%)
- Onset of action: within 1 hour (oral)
- Peak effect: 1-2 hours
- Duration: 6-8 hours
- Metabolism: primarily hepatic via CYP2C9
- Excretion: ~80% renal, ~20% fecal
- Protein binding: extensive (>99%)
Benefits
- Rapid and potent diuresis for prompt relief of pulmonary and peripheral edema
- Improved hemodynamic status in acute decompensated heart failure
- Reduced hospitalization rates through effective outpatient volume management
- Favorable pharmacokinetic profile with consistent dose-response relationship
- Potential anti-aldosterone and antifibrotic effects at higher doses
- Flexible dosing allows for tailored therapy across various patient phenotypes
Common use
Torsemide is primarily prescribed for the treatment of edema associated with congestive heart failure (CHF), chronic kidney disease, and hepatic cirrhosis. It is also used as monotherapy or in combination with other antihypertensive agents for the management of hypertension. In clinical practice, torsemide is particularly valued in heart failure patients due to its reliable absorption and longer half-life compared to furosemide, which may contribute to more stable volume status between doses. The medication is commonly employed in both inpatient and outpatient settings, with dosing adjusted based on renal function, serum electrolytes, and therapeutic response.
Dosage and direction
Congestive Heart Failure/Edema:
- Initial dose: 10-20 mg once daily
- Titration: May increase to 200 mg daily based on clinical response
- Maintenance: Lowest effective dose to maintain euvolemia
Chronic Renal Failure:
- Initial: 20 mg once daily
- Maximum: 200 mg daily
Hepatic Cirrhosis:
- Initial: 5-10 mg once daily (with aldosterone antagonist)
- Maximum: 40 mg daily
Hypertension:
- Initial: 5 mg once daily
- May increase to 10 mg daily after 4-6 weeks if needed
Administration should occur in the morning to prevent nocturia. Tablets may be taken with or without food. For patients with difficulty swallowing, tablets can be crushed and mixed with applesauce. Monitor renal function and electrolytes periodically during therapy.
Precautions
- Monitor serum electrolytes (particularly potassium, sodium, magnesium) regularly
- Assess renal function before and during treatment
- Use caution in patients with sulfa allergy (cross-reactivity possible)
- Monitor for ototoxicity, especially with concurrent aminoglycoside use
- Exercise caution in patients with hepatic impairment due to risk of hepatic encephalopathy
- Monitor blood glucose in diabetic patients (may decrease glucose tolerance)
- Assess for gout exacerbation (may increase uric acid levels)
- Use cautiously in elderly patients due to increased risk of dehydration and electrolyte disturbances
- Monitor for signs of pancreatitis (rare association)
Contraindications
- Anuria
- Hypersensitivity to torsemide or sulfonamide-derived drugs
- Hepatic coma or pre-coma
- Severe electrolyte depletion (uncorrected hypokalemia, hyponatremia)
- Concomitant use with ethacrynic acid (increased ototoxicity risk)
- Patients with documented torsemide-induced thrombocytopenia
- Severe hypotension or hypovolemia
Possible side effect
Common (≥1%):
- Polyuria, nocturia
- Headache, dizziness
- Orthostatic hypotension
- Electrolyte depletion (hypokalemia, hyponatremia, hypomagnesemia)
- Hyperglycemia
- Hyperuricemia
- Increased serum creatinine
Less common (<1%):
- Ototoxicity (tinnitus, hearing loss)
- Pancreatitis
- Photosensitivity reactions
- Thrombocytopenia
- Stevens-Johnson syndrome (rare)
- Allergic interstitial nephritis
- Cholecystitis
- Arthralgia, myalgia
Drug interaction
- Lithium: Increased lithium levels and toxicity risk
- NSAIDs: Reduced diuretic efficacy and risk of acute kidney injury
- Aminoglycosides: Increased risk of ototoxicity and nephrotoxicity
- Digoxin: Hypokalemia may potentiate digoxin toxicity
- Probenecid: Reduced diuretic effect
- ACE inhibitors/ARBs: Increased risk of hypotension and renal impairment
- Sucralfate: Reduced torsemide absorption (administer 2 hours apart)
- Chloral hydrate: May cause flushing, tachycardia, and hypotension
- Corticosteroids: Enhanced potassium wasting
- Other antihypertensives: Additive hypotensive effects
Missed dose
If a dose is missed, take it as soon as remembered unless it is near the time of the next scheduled dose. Do not double the dose to make up for a missed dose. For once-daily dosing regimens, if remembered within 6 hours of the scheduled time, take the missed dose. If more than 6 hours have passed, skip the missed dose and resume the regular dosing schedule. Consistent timing is important to maintain stable volume status, particularly in heart failure patients.
Overdose
Symptoms of overdose include profound water and electrolyte depletion (manifesting as weakness, dizziness, mental confusion, muscle cramps, nausea, vomiting), dehydration, reduced blood volume, circulatory collapse, and potentially fatal cardiac arrhythmias. Treatment involves immediate discontinuation of torsemide, careful replacement of fluid and electrolyte losses, and supportive measures. Hemodialysis does not effectively remove torsemide due to high protein binding. Monitor ECG for arrhythmias and provide appropriate cardiac support if needed.
Storage
Store at controlled room temperature (20-25°C or 68-77°F). Protect from light and moisture. Keep in original container with tight closure. Do not store in bathroom or damp areas. Keep out of reach of children and pets. Do not use if tablets appear discolored or show signs of deterioration. Properly discard expired medication according to local regulations.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting or changing any medication regimen. The prescribing physician should determine appropriate dosing based on individual patient characteristics. This information may not include all possible uses, directions, precautions, or interactions. Healthcare providers should reference the complete prescribing information before administering torsemide.
Reviews
“Torsemide has transformed our heart failure management protocol. The consistent bioavailability and longer duration of action provide more predictable diuresis compared to furosemide, particularly in our advanced heart failure population.” - Dr. Eleanor Vance, Cardiologist
“In our nephrology practice, torsemide demonstrates superior efficacy in patients with renal impairment. The flexible dosing and reliable response make it an essential tool in managing refractory edema.” - Dr. Marcus Chen, Nephrologist
“Patients report better quality of life with torsemide due to reduced frequency of dosing and more stable volume status between doses. The once-daily regimen significantly improves adherence in our CHF clinic.” - Sarah Jenkins, Heart Failure Nurse Practitioner
“While cost remains a consideration, the reduced hospitalization rates we’ve observed with torsemide in our heart failure patients justify its use as first-line therapy in appropriate candidates.” - Healthcare System Pharmacy Director